Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia's DA-1726 Cuts Liver Fat 68% and Weight 13.5% in Phase 1 Part 3B Interim

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.319
Mkt Cap
$8.828M
52W Low
$0.966
52W High
$14.85
52W Position info
37% above low
Off High info
91% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

MTVA sits 37% above its 52-week low of $0.966 on elevated volume (1.8× avg).

Summary

MetaVia reported interim Phase 1 Part 3B data showing DA-1726 cut liver fat 68% and body weight 13.5% versus placebo at 16 weeks, with no new GI adverse events after Week 9. The result supports a planned 48-week Phase 2 in MetALD/ALD starting 2H 2027, but the company needs financing to fund it.


Key Events · Product Development and Regulatory · MTVA

  • 68% Placebo-Adjusted Liver Fat Cut

    At Day 109 (~16 weeks), DA-1726 produced a 68% placebo-adjusted liver fat reduction (MRI-PDFF, GMR 0.32, p<0.001) in the MRI substudy of 12 active and 4 placebo participants; 10 of 12 (83%) hit at least a 30% relative reduction versus none on placebo.

  • 13.5% Weight Loss, HbA1c Down

    Body weight fell 12.19 kg (-11.9%) from a 98.6 kg baseline, a 13.5% placebo-adjusted difference (n=15 vs 4, p<0.001), while HbA1c dropped 0.44 pp to 5.33% (-0.24 pp placebo-adjusted, p=0.006) in non-diabetic participants.

  • Cleaner Tolerability After Week 9

    No new GI adverse events were reported after Week 9 (Day 63) through Day 109 and no participant discontinued for a GI event; one serious adverse event of severe vomiting was possibly related and the participant recovered.

  • Phase 2 MetALD/ALD Targeted 2H 2027

    MetaVia plans a 48-week, non-biopsy Phase 2 in up to 150 MetALD/ALD subjects starting 2H 2027, with full Part 3A and Part 3B data expected in Q1 2027.


Analysis · MTVA · Life Sciences

This is the first hard efficacy readout on DA-1726, and it is strong on all three axes the company needs: 68% placebo-adjusted liver fat reduction, 13.5% placebo-adjusted weight loss and a 0.24 pp placebo-adjusted HbA1c drop, all at 16 weeks with no new GI adverse events after Week 9 and no GI-driven discontinuations. For a company with a $12.6M cash balance as of June 30, 2026 and a runway only into 1Q 2027, the data are the main lever for raising the capital the 2027 programs require — the presentation itself says those programs are contingent on additional financing. The caveats are real: tiny arms (n=15 active vs 4 placebo; MRI substudy n=12 vs 4), interim rather than final data, and the liver-disease Phase 2 does not start until 2H 2027. Full Part 3A/3B topline in Q1 2027 is the next hard checkpoint.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.97 to $14.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 18, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.05 info
Change: -$0.180 (-15%) info
Market Cap: $6.81M info
MTVA
Nov 16, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $1.05 info
Change: -$0.220 (-17%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.05 info
Change: -$0.350 (-25%) info
Market Cap: $6.81M info